Blog
RSS FeedPosted by Michael Wonder on 08 Aug 2016
SMC - August 2016 decisions
8 August 2016 - Treatments for blood cancer, skin cancer and high cholesterol among six new medicines accepted for routine use ...
Posted by Michael Wonder on 08 Aug 2016
Decision relating to enoxaparin sodium and plerixafor
8 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis New Zealand Limited (Sanofi) for ...
Posted by Michael Wonder on 08 Aug 2016
Decision relating to idarucizumab and dabigatran
8 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Boehringer Ingelheim NZ Limited for the ...
Posted by Michael Wonder on 06 Aug 2016
The FDA approves first generic version of widely used influenza drug Tamiflu
On August 3, 2016, the U.S. FDA approved the first generic version of Tamiflu (oseltamivir phosphate), a widely used medication ...
Posted by Michael Wonder on 06 Aug 2016
Brivaracetam in epilepsy: additional clinical benefits not seen as before
4 August 2016 - The new indirect comparison is methodologically better but there is still no evidence of an additional ...
Posted by Michael Wonder on 06 Aug 2016
ITM´s subsidiary ITG receives drug approval for EndolucinBeta
4 August 2016 - ITM Isotopen Technologien München AG today announced that the EMA has granted marketing authorization for EndolucinBeta of ...
Posted by Michael Wonder on 05 Aug 2016
Agreement for supply of influenza vaccine approved by PHARMAC
5 August 2016 - PHARMAC is pleased to announce the approval of an agreement with BGP Products Pty Ltd (trading as ...
Posted by Michael Wonder on 04 Aug 2016
NICE issues draft guidance on the use of lesinurad
3 August 2016 - NICE has issued draft guidance on the use of lesinurad (Zurampic) for the treatment of patients ...
Posted by Michael Wonder on 04 Aug 2016
NICE draft guidance recommends new drug for people with ankylosing spondylitis
4 August 2016 - New draft guidance from NICE means thousands of people with back condition ankylosing spondylitis will soon have ...
Posted by Michael Wonder on 03 Aug 2016
NICE issues draft guidance on the use of Otezla (apremilast)
3 August 2016 - NICE has issued draft guidance on the use of apremilast for the treatment of patients with moderate ...
Posted by Michael Wonder on 03 Aug 2016
Merck’s Keytruda (pembrolizumab) approved by the European Commission for patients with advanced non-small cell lung cancer whose tumors express PD-L1
3 August 2016 - Approval based on trial results demonstrating superior overall survival compared to chemotherapy in previously-treated patients. ...
Posted by Michael Wonder on 03 Aug 2016
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA breakthrough therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
3 August 2016 - Designation underscores the continuing unmet need of the HR+/HER2- advanced breast cancer population and the potential of ...
Posted by Michael Wonder on 03 Aug 2016
Ramucirumab in gastric cancer: no sign of an additional clinical benefit
1 August 2016 - Former orphan drug undergoes regular early benefit assessment; submitted studies unsuitable for assessment. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in advanced lung cancer: evidence for significant additional benefits
1 August 2016 - Advantages in overall survival and side effects. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in renal cell carcinoma: indication of additional clinical benefits
1 August 2016 - Benefits in overall survival, morbidity and side effects. ...